Literature DB >> 10680015

Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model.

J Gómez-Navarro1, J L Contreras, W Arafat, X L Jiang, D Krisky, T Oligino, P Marconi, B Hubbard, J C Glorioso, D T Curiel, J M Thomas.   

Abstract

To develop a cellular vehicle able to reach systemically disseminated areas of angiogenesis, we sought to exploit the natural tropism of circulating endothelial progenitor cells (EPCs). Primate CD34+ EPCs were genetically modified with high efficiency and minimal toxicity using a non-replicative herpes virus vector. These EPCs localized in a skin autograft model of angiogenesis in rhesus monkeys, and sustained the expression of a reporter gene for several weeks while circulating in the blood. In animals infused with autologous CD34+ EPCs transduced with a thymidine kinase-encoding herpes virus, skin autografts and subcutaneous Matrigel pellets impregnated with vascular growth factors underwent necrosis or accelerated regression after administration of ganciclovir. Importantly, the whole intervention was perfectly well tolerated. The accessibility, easy manipulation, lack of immunogenicity of the autologous CD34+ cell vehicles, and tropism for areas of angiogenesis render autologous CD34+ circulating endothelial progenitors as ideal candidates for exploration of their use as cellular vehicles when systemic gene delivery to those areas is required. Gene Therapy (2000) 7, 43-52.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10680015     DOI: 10.1038/sj.gt.3301054

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

1.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 2.  Does CCL19 act as a double-edged sword in cancer development?

Authors:  Arezoo Gowhari Shabgah; Zaid Mahdi Jaber Al-Obaidi; Heshu Sulaiman Rahman; Walid Kamal Abdelbasset; Wanich Suksatan; Dmitry O Bokov; Lakshmi Thangavelu; Abduladheem Turki Jalil; Farhad Jadidi-Niaragh; Hamed Mohammadi; Kazem Mashayekhi; Jamshid Gholizadeh Navashenaq
Journal:  Clin Exp Immunol       Date:  2022-04-04       Impact factor: 4.330

3.  Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Authors:  Timothy Kottke; Rosa M Diaz; Karen Kaluza; Jose Pulido; Feorillo Galivo; Phonphimon Wongthida; Jill Thompson; Candice Willmon; Glen N Barber; John Chester; Peter Selby; Scott Strome; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

4.  Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.

Authors:  Timothy Kottke; Feorillo Galivo; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Dragan Jevremovic; Glen N Barber; Geoff Hall; John Chester; Peter Selby; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-04-22       Impact factor: 11.454

5.  Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Authors:  J Qiao; H Wang; T Kottke; R M Diaz; C Willmon; A Hudacek; J Thompson; K Parato; J Bell; J Naik; J Chester; P Selby; K Harrington; A Melcher; R G Vile
Journal:  Gene Ther       Date:  2008-02-28       Impact factor: 5.250

Review 6.  Promising Strategies for Preserving Adult Endothelium Health and Reversing Its Dysfunction: From Liquid Biopsy to New Omics Technologies and Noninvasive Circulating Biomarkers.

Authors:  Carmela Rita Balistreri
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

7.  AC133+ progenitor cells as gene delivery vehicle and cellular probe in subcutaneous tumor models: a preliminary study.

Authors:  Ali M Rad; A S M Iskander; Branislava Janic; Robert A Knight; Ali S Arbab; Hamid Soltanian-Zadeh
Journal:  BMC Biotechnol       Date:  2009-03-27       Impact factor: 2.563

Review 8.  Are Endothelial Progenitor Cells the Real Solution for Cardiovascular Diseases? Focus on Controversies and Perspectives.

Authors:  Carmela R Balistreri; Silvio Buffa; Calogera Pisano; Domenico Lio; Giovanni Ruvolo; Giuseppe Mazzesi
Journal:  Biomed Res Int       Date:  2015-10-05       Impact factor: 3.411

9.  Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region.

Authors:  Ildiko Toma; Paul J Kim; Rajesh Dash; Michael V McConnell; Dwight Nishimura; Phillip Harnish; Phillip C Yang
Journal:  Cardiovasc Diabetol       Date:  2016-02-05       Impact factor: 9.951

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.